GlassScriptPhysician profile
Scott W Kemp
NPI 1982925517
$16,571.53
in general payments reported to CMS, 2019-2025
46 companies · $1,870 in 2025
The $1,870 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,197 · 2020: $1,934 · 2021: $2,655 · 2022: $2,650 · 2023: $2,941 · 2024: $2,324 · 2025: $1,870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,135.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,023.29 | 2019-2025 | |
| Novo Nordisk INC | $1,817.30 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $1,757.61 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,562.82 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,458.26 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,113.67 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $806.91 | 2019-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $545.39 | 2019-2024 | Trintellix |
| Merck Sharp & Dohme LLC | $523.54 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $445.71 | 2019-2024 | Xifaxan |
| Corium, LLC | $413.24 | 2023-2025 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $399.58 | 2019-2025 | Jardiance, Ofev |
| Daiichi Sankyo INC. | $353.68 | 2019-2023 | Injectafer |
| Amgen INC. | $305.14 | 2021-2025 | Otezla, Repatha, Krystexxa |
| Amarin Pharma, INC. | $278.38 | 2019-2021 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Kemp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.